Anna Berkenblit

4.9k total citations · 2 hit papers
57 papers, 3.2k citations indexed

About

Anna Berkenblit is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Anna Berkenblit has authored 57 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 25 papers in Molecular Biology and 20 papers in Oncology. Recurrent topics in Anna Berkenblit's work include Renal cell carcinoma treatment (20 papers), Cancer Genomics and Diagnostics (11 papers) and Renal and related cancers (9 papers). Anna Berkenblit is often cited by papers focused on Renal cell carcinoma treatment (20 papers), Cancer Genomics and Diagnostics (11 papers) and Renal and related cancers (9 papers). Anna Berkenblit collaborates with scholars based in United States, Poland and France. Anna Berkenblit's co-authors include John M. Lambert, Andrew Strahs, Mizue Krygowski, Jay Feingold, Stephen A. Cannistra, Jill S. Clancy, Janice P. Dutcher, Gary R. Hudes, Laurence Moore and Cezary Szczylik and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Anna Berkenblit

57 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

2009 485 citations Georg Heß, Andrew Strahs et al. Journal of Clinical Oncology profile →
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

2021 186 citations Kathleen N. Moore, Nicoletta Colombo et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Berkenblit United States	26	1.6k	1.4k	1.3k	710	569	57	3.2k
J. Thaddeus Beck United States	29	1.3k 0.8×	2.6k 1.9×	1.3k 1.0×	623 0.9×	420 0.7×	113	3.7k
Paul Frankel United States	34	1.8k 1.1×	1.9k 1.4×	967 0.8×	658 0.9×	337 0.6×	214	4.1k
Wael A. Harb United States	23	923 0.6×	1.4k 1.0×	759 0.6×	423 0.6×	247 0.4×	118	2.5k
Tiffany A. Traina United States	30	1.1k 0.7×	2.4k 1.7×	1.4k 1.1×	1.6k 2.2×	418 0.7×	146	4.0k
Stacy Moulder United States	29	1.7k 1.1×	2.7k 1.9×	2.6k 2.0×	1.6k 2.2×	443 0.8×	70	4.7k
Stephen D. Rubin United States	13	1.1k 0.7×	2.6k 1.9×	1.3k 1.0×	673 0.9×	150 0.3×	17	4.0k
Zsuzsanna Pápai Hungary	20	1.2k 0.7×	1.7k 1.2×	1.6k 1.2×	951 1.3×	360 0.6×	94	3.2k
Drew Rasco United States	33	1.7k 1.1×	2.4k 1.7×	980 0.8×	516 0.7×	422 0.7×	192	4.1k
Ingunn M. Stefansson Norway	36	2.2k 1.4×	1.5k 1.1×	552 0.4×	1.3k 1.9×	462 0.8×	73	4.4k
Mónica Arnedos France	25	1.4k 0.8×	1.6k 1.2×	1.0k 0.8×	1.2k 1.7×	293 0.5×	90	3.1k

Countries citing papers authored by Anna Berkenblit

Since Specialization

Citations

This map shows the geographic impact of Anna Berkenblit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Berkenblit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Berkenblit more than expected).

Fields of papers citing papers by Anna Berkenblit

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Berkenblit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Berkenblit. The network helps show where Anna Berkenblit may publish in the future.

Co-authorship network of co-authors of Anna Berkenblit

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Berkenblit. A scholar is included among the top collaborators of Anna Berkenblit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Berkenblit. Anna Berkenblit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Picozzi, Vincent J., Anna M. Varghese, Paul E. Oberstein, et al.. (2025). Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP) Bayesian platform trial.. Journal of Clinical Oncology. 43(4_suppl). 673–673. 1 indexed citations

Moore, Kathleen N., Antoine Angelergues, Gottfried E. Konecny, et al.. (2023). Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.. Journal of Clinical Oncology. 41(17_suppl). LBA5507–LBA5507. 37 indexed citations

Tu, Ya‐Ping, H. Maxime Lagraauw, Callum M. Sloss, et al.. (2023). Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐α positive ovarian cancer: The antibody–drug conjugate, payload and metabolite. British Journal of Clinical Pharmacology. 90(2). 568–581. 5 indexed citations

Martin, Lainie P., Jason Konner, Kathleen N. Moore, et al.. (2017). Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecologic Oncology. 147(2). 402–407. 104 indexed citations

Wolff, Antonio C., Ann Lazar, Igor Bondarenko, et al.. (2012). Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology. 31(2). 195–202. 222 indexed citations

Maroto, Pablo, Gary R. Hudes, Janice P. Dutcher, et al.. (2011). Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus. Journal of Clinical Oncology. 29(13). 1750–1756. 83 indexed citations

Geoerger, Birgit, Mark W. Kieran, Stephan A. Grupp, et al.. (2011). Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. European Journal of Cancer. 48(2). 253–262. 103 indexed citations

Heß, Georg, Sonali M. Smith, Anna Berkenblit, & Bertrand Coiffier. (2009). Temsirolimus in Mantle Cell Lymphoma and Other Non-Hodgkin Lymphoma Subtypes. Seminars in Oncology. 36. S37–S45. 23 indexed citations

Figlin, Robert A., Paul de Souza, David F. McDermott, et al.. (2009). Analysis of PTEN and HIF‐1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon‐α. Cancer. 115(16). 3651–3660. 67 indexed citations

10.

Hudes, Gary R., Anna Berkenblit, Jay Feingold, et al.. (2009). Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma. Seminars in Oncology. 36. S26–S36. 44 indexed citations

11.

Buckner, Jan C., Bahram Forouzesh, Charles Erlichman, et al.. (2009). Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Investigational New Drugs. 28(3). 334–342. 37 indexed citations

12.

Dutcher, Janice P., Paul de Souza, David F. McDermott, et al.. (2009). Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Medical Oncology. 26(2). 202–209. 194 indexed citations

13.

Hudes, G. R., Charles S. White, Mizue Krygowski, et al.. (2009). 7113 Radiographic findings of drug-induced pneumonitis and clinical correlation in patients with advanced renal cell carcinoma treated with temsirolimus. European Journal of Cancer Supplements. 7(2). 426–427. 9 indexed citations

14.

Bellmunt, Joaquim, Cezary Szczylik, Jay Feingold, Andrew Strahs, & Anna Berkenblit. (2008). Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Annals of Oncology. 19(8). 1387–1392. 129 indexed citations

15.

Evans, Devon, Thomas J. Miner, David A. Iannitti, et al.. (2007). Docetaxel, Capecitabine and Carboplatin in Metastatic Esophagogastric Cancer: A Phase II Study. Cancer Investigation. 25(6). 445–448. 11 indexed citations

16.

Tsai, James, David A. Iannitti, Anna Berkenblit, et al.. (2005). Phase I Study of Docetaxel, Capecitabine, and Carboplatin in Metastatic Esophagogastric Cancer. American Journal of Clinical Oncology. 28(4). 329–333. 9 indexed citations

17.

Berkenblit, Anna, Ursula A. Matulonis, Joan F. Kroener, et al.. (2005). Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial. Gynecologic Oncology. 99(1). 50–57. 56 indexed citations

18.

Berkenblit, Anna, Michael V. Seiden, Ursula A. Matulonis, et al.. (2004). A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecologic Oncology. 95(3). 624–631. 34 indexed citations

19.

Berkenblit, Anna, et al.. (2004). STA-4783, a novel HSP inducer, enhances paclitaxel activity—Preclinical to clinical modeling. Journal of Clinical Oncology. 22(14_suppl). 3124–3124. 4 indexed citations

20.

Berkenblit, Anna, et al.. (2003). Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin. Gynecologic Oncology. 89(3). 486–493. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact